Matthew M. Walsh - 31 Mar 2025 Form 4 Insider Report for Organon & Co. (OGN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Apr 2025, 17:41:53 UTC
Prior SEC filing
24 Feb 2025
Next SEC filing
06 May 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Matthew M. Walsh

Key filing fact

Matthew M. Walsh filed Form 4 for Organon & Co. (OGN) on 02 Apr 2025.

Key facts

  • This page summarizes Matthew M. Walsh's Form 4 filing for Organon & Co. (OGN).
  • 11 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 02 Apr 2025, 17:41.

Change

  • Previous filing in this sequence was filed on 24 Feb 2025.
  • Current net transaction value: -$249,195.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OGN transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+15,070
Change %
+13%
Price
$0.000000
Shares after
130,458
Date
31 Mar 2025
Ownership
Direct
OGN transaction

Common Stock

Tax liability

Transaction value
$107,693
Shares
-7,422
Change %
-5.7%
Price
$14.51
Shares after
123,036
Date
31 Mar 2025
Ownership
Direct
Footnotes
F1
OGN transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+12,046
Change %
+9.8%
Price
$0.000000
Shares after
135,082
Date
31 Mar 2025
Ownership
Direct
OGN transaction

Common Stock

Tax liability

Transaction value
$86,088
Shares
-5,933
Change %
-4.4%
Price
$14.51
Shares after
129,149
Date
31 Mar 2025
Ownership
Direct
Footnotes
F1
OGN transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+7,754
Change %
+6%
Price
$0.000000
Shares after
136,903
Date
31 Mar 2025
Ownership
Direct
OGN transaction

Common Stock

Tax liability

Transaction value
$55,414
Shares
-3,819
Change %
-2.8%
Price
$14.51
Shares after
133,084
Date
31 Mar 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OGN transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+317,656
Change %
Price
$0.000000
Shares after
317,656
Date
31 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
317,656
Exercise price
$14.89
Footnotes
F2
OGN transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+64,640
Change %
Price
$0.000000
Shares after
64,640
Date
31 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
64,640
Exercise price
Footnotes
F3, F4
OGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-15,070
Change %
-33%
Price
$0.000000
Shares after
30,142
Date
31 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,070
Exercise price
Footnotes
F3, F5
OGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-12,046
Change %
-50%
Price
$0.000000
Shares after
12,047
Date
31 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,046
Exercise price
Footnotes
F3, F6
OGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-7,754
Change %
-100%
Price
$0.000000
Shares after
0
Date
31 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,754
Exercise price
Footnotes
F3, F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 28, 2025, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

Footnote F2

The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2026, March 31, 2027, and March 31, 2028.

Footnote F3

Each RSU converts into one share of Organon common stock.

Footnote F4

The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On March 31, 2025, RSUs were granted and will vest in three equal installments on each of March 31, 2026, March 31, 2027, and March 31, 2028.

Footnote F5

On March 29, 2024, RSUs were granted and on March 29, 2025, one-third of these RSUs vested, with the remaining RSUs to vest on March 29, 2026, and March 29, 2027. Since the first anniversary of the date of grant was on Saturday, March 29, 2025, the vesting occurred on Monday, March 31, 2025, the next business day.

Footnote F6

On March 31, 2023, RSUs were awarded and on March 31, 2025, one-third of these RSUs vested with the remaining RSUs to vest on March 31, 2026.

Footnote F7

On March 31, 2022, RSUs were awarded and on March 31, 2025, the final third of these RSUs vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .